Cargando…

Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers

Checkpoint blockade therapy is effective against many cancers; however, new targets need to be identified to treat patients who do not respond to current treatment or demonstrate immune escape. Here, we showed that blocking the inhibitory receptor Killer cell lectin-like receptor G1 (KLRG1) enhances...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tata, Angela, Dodard, Garvin, Fugère, Céline, Leget, Corinne, Ors, Mélody, Rossi, Benjamin, Vivier, Eric, Brossay, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8208121/ https://www.ncbi.nlm.nih.gov/pubmed/34188973 http://dx.doi.org/10.1080/2162402X.2021.1933808

Ejemplares similares

A Protocol for the Production of KLRG1 Tetramer
por: Terrizzi, Stephanie C., et al.
Publicado: (2010)

The Yin and Yang of Targeting KLRG1(+) Tregs and Effector Cells
por: Borys, Samantha M., et al.
Publicado: (2022)

PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127(+) and KLRG1(+) CD8 T cells
por: Hui, Zhenzhen, et al.
Publicado: (2023)

PD-1 regulates KLRG1(+) group 2 innate lymphoid cells
por: Taylor, Samuel, et al.
Publicado: (2017)

Increased KLRG1 and PD-1 expression on CD8 T lymphocytes in TB-IRIS
por: Goovaerts, Odin, et al.
Publicado: (2019)

KLRG1 restricts memory T cell antitumor immunity
por: Li, Lei, et al.
Publicado: (2016)

Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy
por: Yang, Xiaodong, et al.
Publicado: (2021)

KLRG1(+) natural killer cells protect against pulmonary metastatic disease by immunosurveillance
por: Renner, Philipp, et al.
Publicado: (2014)

CD154 Blockade Alters Innate Immune Cell Recruitment and Programs Alloreactive CD8(+) T Cells into KLRG-1(high) Short-Lived Effector T Cells
por: Ferrer, Ivana R., et al.
Publicado: (2012)

Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1(+) KLRG1(−) CD4(+) T cells
por: Bull, N. C., et al.
Publicado: (2018)

Early primed KLRG1(-) CMV-specific T cells determine the size of the inflationary T cell pool
por: Baumann, Nicolas S., et al.
Publicado: (2019)

Coexpression of PD-1, 2B4, CD160 and KLRG1 on Exhausted HCV-Specific CD8+ T Cells Is Linked to Antigen Recognition and T Cell Differentiation
por: Bengsch, Bertram, et al.
Publicado: (2010)

Ptpn11 Deletion in CD4(+) Cells Does Not Affect T Cell Development and Functions but Causes Cartilage Tumors in a T Cell-Independent Manner
por: Miah, S. M. Shahjahan, et al.
Publicado: (2017)

Allogeneic dendritic cells induce potent antitumor immunity by activating KLRG1(+)CD8 T cells
por: Wang, Chao, et al.
Publicado: (2019)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

KLRG1 and CD103 Expressions Define Distinct Intestinal Tissue-Resident Memory CD8 T Cell Subsets Modulated in Crohn's Disease
por: Bottois, Hugo, et al.
Publicado: (2020)

Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models
por: Greenberg, Steven A., et al.
Publicado: (2019)

Reduced Ebola vaccine responses in CMV(+) young adults is associated with expansion of CD57(+)KLRG1(+) T cells
por: Bowyer, Georgina, et al.
Publicado: (2020)

Ptpn2 and KLRG1 regulate the generation and function of tissue-resident memory CD8(+) T cells in skin
por: Hochheiser, Katharina, et al.
Publicado: (2021)

KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response
por: Ager, Casey R, et al.
Publicado: (2023)

In Vivo Zymosan Treatment Induces IL15-Secreting Macrophages and KLRG1-Expressing NK Cells in Mice
por: Park, Hyun Jung, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Expression of IL‐7Rα and KLRG1 defines functionally distinct CD8(+) T‐cell populations in humans
por: Remmerswaal, Ester B. M., et al.
Publicado: (2019)

KLRG1 expression on natural killer cells is associated with HIV persistence, and its targeting promotes the reduction of the viral reservoir
por: Astorga-Gamaza, Antonio, et al.
Publicado: (2023)

Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
por: McCaughan, Georgia J. B., et al.
Publicado: (2016)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

PD-1 Blockade in Anaplastic Thyroid Carcinoma
por: Capdevila, Jaume, et al.
Publicado: (2020)

Biomarkers of response to PD-1 pathway blockade
por: Li, Hanxiao, et al.
Publicado: (2022)

IL-25-responsive, lineage-negative KLRG1(hi) cells are multipotential “inflammatory” type 2 innate lymphoid cells
por: Huang, Yuefeng, et al.
Publicado: (2014)

Expression of KLRG1 and CD127 defines distinct CD8(+) subsets that differentially impact patient outcome in follicular lymphoma
por: Wu, Hongyan, et al.
Publicado: (2021)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rddt5qisqn4gice0hi6mu91bu6